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Small Molecule Inhibitor Design for  
Anaplastic Lymphoma Kinase Inhibition 
THEODORE D. HANSEL, DAVID J. GRABOVSKY 
The Anaplastic Lymphoma Kinase (ALK) gene has been linked to tumorigenesis in a number of 
human cancers, including anaplastic large cell lymphoma (ALCL) and neuroblastoma. While ALK 
mutations in ALCL and many other cancers occur as a result of gene fusions with wild type kinase 
domains, those in neuroblastoma stem from single nucleotide polymorphisms (SNPs) in the kinase 
domain. These lead to autophosphorylation and constitutive signaling by ALK for cell growth and 
division, ultimately causing cancer. Crizotinib, an ATP-competitive ALK inhibitor, has proven to be an 
effective inhibitor of both ALKWT and ALKMutant kinase domains, and is in the middle of clinical trials for 
neuroblastoma treatment. This review used the PyMOL and AutoDock Vina computational biology 
programs to predict the binding affinities of Crizotinib, Ceritinib (LDK378), and PF-922 to three different 
ALK kinase mutations in order to determine the most effective inhibitor. The EGFR inhibitors gefitinib 
and erlotinib were also analyzed in complex with ALK as negative controls to verify the specificity of the 
ALK inhibitors. The crystalline complexes were then qualitatively analyzed to uncover the mechanics 
behind the docking results. Based on the results generated by Vina, PF-922, representative of the second 
generation of ALK inhibitors, is predicted to be the most effective out of the tested compounds. These 
results may be used to predict the inhibitor that will require the lowest dosage to achieve the greatest 
inhibitory effect, hopefully leading to fewer side effects from treatment. 
 
Introduction 
The Anaplastic Lymphoma Kinase (ALK) receptor 
tyrosine kinase has been implicated as a major oncogene in 
a variety of different cancers, ranging from adult non-small 
cell lung cancer (NSCLC) and anaplastic large-cell 
lymphoma (ALCL) to neuroblastoma in children1. The 
majority of these mutations are fusion proteins, such as 
NPM-ALK in ALCL2 or EML4-ALK in NSCLC3. In these 
fusion proteins, the ALK kinase domain generally remains 
intact and wild type. However, ALK mutations in 
neuroblastoma are unique as they are frequently point 
mutations within the kinase domain. The mutations may be 
somatic or germline, with those causing tumorigenesis 
leading to constitutively active kinase domains4. Crizotinib 
is a dual ALK/MET inhibitor produced by Pfizer, and was 
one of the first ALK inhibitors introduced. Although first 
used with non-mutated (WT) ALK kinase domains in 
NSCLC, Crizotinib has also demonstrated efficacy 
preclinically in ALKMut cell lines, and clinically in Phase I 
clinical trial patients5. 
For the purposes of this review, the PyMOL and 
AutoDock Vina computational programs were used to 
compare the binding affinity of Crizotinib with that of ATP, 
the natural ligand, as well as other ALK inhibitors. These 
other inhibitors include Ceritinib (LDK378) produced by 
Novartis, and a second-generation ALK inhibitor designed 
by Pfizer called PF-06463922 (PF-922). All of these inhibitors 
are ATP-competitive and function by binding preferentially 
to the ALK kinase domain and preventing ATP from 
entering the binding pocket, inhibiting the kinase activity. 
Theoretically, a higher binding affinity correlates with 
greater efficacy and reduced dosages to achieve the same 
inhibitory effect. In vitro, this effect would be shown by 
measuring ALK inhibition through western blotting or 
ELIZA assays. This review analyzes the binding affinities 
associated with each ligand, in addition to one designed for 
this study, for three different ALK point mutations. The 
first, C1097S, is used as a stand-in for the WT kinase 
domain found in ALK fusion proteins. This mutation 
stabilizes the model of the ALK kinase domain, and is 
found in all other models of the protein6. The R1275Q 
mutation represents the most common neuroblastoma 
mutation, while the F1174L mutation is the most resistant 
mutation commonly seen in the clinical setting7. 
Methods 
AutoDock Vina is a molecular docking program 
that takes in the molecular structures of a receptor and a 
ligand, runs computations simulating the ligand’s docking 
into a specified binding pocket on the receptor, and predicts 
the ligand’s binding affinity to its receptor8. Using 
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structures for the C1097S, R1275Q, and F1174L ALK 
mutations6, as well as for each inhibitor9–11, a docking 
analysis in Vina for each ligand-receptor pairing was run to 
determine binding affinities for each pairing. Vina also 
produces files containing the ligand’s docked pose 
responsible for the reported affinity; these files were opened 
in the PyMOL molecular viewer and analyzed qualitatively 
in terms of their conformations. 
Before running Vina, special .pdbqt files describing 
each molecule involved in docking were prepared. PDB 
files (descriptions of the spatial arrangement and types of 
atoms in a molecule) containing each compound’s structure 
were downloaded from pdb.org and isolated in PyMOL. 
ALKWT was downloaded in complex with a piperidine-
carboxamide inhibitor6, which was removed; the other two 
ALK mutations were downloaded in apo6 (ligand-free) 
form. All three drugs (Crizotinib, Ceritinib, and PF-922) 
were originally downloaded in complex with ALK9–11, 
which was subsequently removed from each ligand. 
Each ligand file was then opened in AutoDockTools 
(ADT), a GUI extension of Vina, and subsequently saved in 
.pdbqt format, which preserves the atom locations specified 
in PDB format, but also gives each atom partial charges (q) 
and an AutoDock-specific atom type (t). The same was done 
with each receptor; however, crystallographic water 
molecules were removed and polar hydrogens were added 
(as preferred by Vina) before saving each file in .pdbqt 
format. The final step in molecule preparation involved 
defining a search space on the receptors where Vina would 
search for a binding pocket. Each protein was visually 
inspected in ADT until the binding site was found; the 
search space was then specified as a box around the binding 
site, with (x, y, z) coordinates for its center and x, y, and z-
lengths for its sides. 
Once the .pdbqt files for all receptors and proteins 
were saved, a configuration (config) file was written and 
Vina was run. The config file gave Vina the filenames of the 
ligand and receptor to be docked, as well as the coordinates 
and size of the search space box found graphically in ADT. 
(See Appendix A for the format and parameters of the 
config file.) Vina was run from a Windows command 
prompt: after changing the computer’s directory to the 
folder where vina.exe was located, the command 
“\Vina\vina.exe” --config conf.txt --log log.txt 
read the config file and created a log of its output as the 
analysis ran.  
 
Vina’s output takes the form of .pdbqt files 
containing each ligand’s 9 most likely docking poses, as 
well as the log of the 9 affinities corresponding to those 
poses.  The .pdbqt files were saved for visualization and 
comparative analysis, and only the highest affinity for each 
docking run, representing the ligand’s most likely pose, was 
recorded. Because Vina uses a random seed for each 
docking run, its results are nondeterministic; the program 
must therefore run several times for each ligand-receptor 
pairing to produce reliable data. Affinities from 10 docking 
runs were recorded in a Microsoft Excel spreadsheet and 
then averaged to produce each pairing’s mean affinity. 
Results: Computational Analysis 
Figures 1 – 5 below summarize the results of our 
study, listing each ligand’s binding affinities to all three 
proteins (A), followed by images of the ligands docked with 
each of the three versions of ALK: C1097S (B), R1275Q (C), 
and F1174L (D). Figure 1 shows data on ATP, Figure 2 on 
Crizotinib, Figure 3 on Ceritinib, Figure 4 on PF-922, and 
Figure 5 on TDH-01, a drug designed by one of the authors 
based on the structure of PF-922.. Comparison of the 
ligands bound to ALKWT shows that PF-922 (Figure 4 (B)) 
and TDH-01 (Figure 5 (B)) both had the highest affinity, 
followed by Crizotinib (Figure 2 (B)), Ceritinib (Figure 3 
(B)), and finally ATP (Figure 1 (B)). Binding affinities 
associated with both mutated proteins exhibited the same 
order, with PF-922 pulling slightly ahead of TDH-01. In 
every simulation, ATP was the weakest binding partner. 
Another table summarizing our results, which compares 
ligands instead of proteins, can be found in Appendix B. 
Comparison of the receptors yielded less obvious 
patterns. ATP bound to ALKWT (Figure 1 (B)) with a lower 
affinity than to ALKF1174L (Figure 1 (D)), but with higher 
affinity than to ALKR1275Q (Figure 1 (C)). Crizotinib did not 
follow this trend, binding weakest to ALKR1275Q (Figure 2 
(C)), slightly stronger to ALKF1174L (Figure 2 (D)), and 
strongest to ALKWT (Figure 2 (B)), for which it was 
designed. Ceritinib behaved differently, binding to 
ALKR1275Q (Figure 3 (C)) with higher affinity than to 
ALKF1174L (Figure 3 (D)); yet still the bond was not as strong 
as to ALKWT (Figure 3 (B)). PF-922, the overall best ALK 
inhibitor, interestingly bound with higher affinity to ALKMut 
proteins (Figure 4 (C-D)) than to ALKWT (Fiure 4 (B)). TDH-
01 also fared better with mutated proteins (Figure 5 (C-D)) 
than with ATPWT (Figure 5 (A)), actually binding best to the 
notoriously resistant ALKF1174L (Figure 5 (D)). These trends 
in PF-922 and TDH-01 show their functional similarity, as 
well as their specificity for mutated ALK variants. 
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Qualitative Comparison 
The binding affinity between a protein and its 
ligand are a direct result of how tightly the ligand fits into 
its binding pocket, as well as how well the ligand matches 
“hot spots” in the pocket. Hot spots are regions in the 
protein of high electrical charge that can create strong 
intermolecular forces to hold the ligand inside the binding 
site. As previously noted, all of the inhibitors demonstrated 
a greater binding affinity than ATP for all ALK mutations, 
which is necessary for the inhibitor to function. By 
analyzing the crystal structure of the inhibitors in complex 
with the ALK kinase domain, it becomes clear that the more 
effective compounds, such as PF-922, TDH-01, and 
Crizotinib, bind more preferably than Ceritinib or ATP.  
Figure 1 (B) shows the crystalline structure of ATP 
in the WT kinase domain. The fit of the molecule inside the 
pocket is relatively loose, and there are only a few hotspots 
linked to electronegative regions in the molecule. These 
explain the relatively low binding affinity. There are even 
some electronegative regions of the molecule near negative 
hotspots, which would suggest repulsion. These same 
principles are also evident in ALKR1275Q in figure 1 (C) and 
ALKF1174L in figure 1 (D). Crizotinib, shown in complex with 
ALKWT in figure 2 (B), has a similar linear structure to that 
of ATP, but features a highly electronegative fluorine 
attached to an aromatic ring, giving it the ability to bind 
with a hot spot in the pocket ATP was unable to reach, 
likely giving Crizotinib its preferential affinity. Crizotinib 
also binds strongly to this hotspot in both ALKR1275Q (figure 
2 (C)) and ALKF1174L (figure 2 (D)). Ceritinib also binds more 
preferentially than ATP to all three ALK mutations (Figure 
3). Since Ceritinib does not appear to directly bind with 
many hot spots, its increased affinity is likely due to a 
tighter fit than ATP’s, although it also features a linear 
structure similar to ATP and Crizotinib but lacks the highly 
interactive fluorine.  
PF-922, representing the second generation ALK 
inhibitors, displays the highest binding affinity out of all of 
the reviewed inhibitors (figure 4 (A)). Like Crizotinib, it 
features the aromatic ring-linked fluorine to strongly bind 
to hot spots, but departs from the linear design in favor of a 
ringed shape. Resulting in an altogether wider molecule in 
the main horizontal plane, PF-922 fits more snugly into the 
binding pocket than the other inhibitors, allowing it gain a 
stronger affinity to the walls of the pocket while interacting 
with particular hotspots (figure 4 (B-D)).  
 
TDH-01 was designed by one of the authors based 
on the PF-922 geometry, and attempted to gain a higher 
binding affinity than PF-922 by creating more regions of 
high electronegativity in the molecule. While TDH-01 
interacted with many of the same hot spots as PF-922 and 
had a nearly identical docking pose, the additional 
electronegativity also increased its repulsion of the binding 
pocket’s negatively charged regions. While also present in 
ALKWT and ALKF1174L (figure 5 (D)), this is especially evident 
with the proximity of the anterior nitrogen atoms and the 
negative region of ALKR1275Q (figure 5 (C)). Figure 6 below is 
a side-by-side comparison of the structures of PF-922 (A) 
and TDH-01 (B). The increased polarity within TDH-01, as 
evidenced by the abundance of fluorine, nitrogen, and 
oxygen atoms, is most likely liable for its slight decrease in 
binding affinity. 
 
Discussion and Conclusion 
Based on our results, PF-922 is predicted to be the 
most effective ALK inhibitor, especially for the resistant 
F1174L mutation. Our data matches that of other published 
studies9. Additionally, the protein models accurately reflect 
the observed in vitro resistance of the F174L ALK mutation 
due to its increased ATP binding affinity12. This review has 
demonstrated the beneficial effect of not only 
conformational compatibility, but also hotspot targeting in 
rational drug design. The inhibitors that demonstrated the 
highest binding affinities were those with the greatest 
amount of conformity to the pocket and those which 
targeted the most hotspots. 
The most obvious path for future research is 
preclinical and clinical testing of these compounds. 
Crizotinib has already proven its efficacy in the clinical 
setting, and the other drugs are also ambling in this 
direction. TDH-01, at present only a theoretical model, 
would have to be produced in the laboratory prior to any 
bench testing. While direct clinical or preclinical 
comparisons of these compounds are unlikely, this review 
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serves as a good basis for the comparison of ALK inhibitor 
efficacy from computational and qualitative perspectives. 
Computational results gathered during preclinical testing of 
new compounds allows researchers to better focus on 
testing drugs with higher chances of success, allowing for 
more efficient use of limited research funding. The current 
process for drug design (high throughput screening) is not 
only laborious, but also incredibly expensive. By integrating 
data gathered through computational methods, 
pharmaceutical engineers may more intelligently create 
drugs, streamlining the development and production of 
more effective novel treatments. 
 
____________________________________
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Appendix A: The Configuration File 
receptor = filename.pdbqt 
ligand = filename.pdbqt 
 
out = out.pdbqt 
 
center_x = 20.0 
center_y = 15.0 
center_z = variable: 
 C1097S: 63 
 R1275Q: 10 
 F1174L: 11 
 
size_x = 20 
size_y = 20 
size_z = 20 
 
exhaustiveness = 8 
 
Appendix B: Average Inhibitor Binding Affinities 
Inhibitors 
 
(kcal/mol) ATP Ceritinib Crizotinib PF-922 TDH-01 
C1097S 6.81 7.9 8.19 9.20 9.20 
R1275Q 6.39 7.51 7.92 10.40 9.70 
F1174L 6.94 7.43 7.99 10.40 10.10 
 
Negative Controls 
 
(kcal/mol) Gefitinib Erlotinib 
C1097S 7.61 6.55 
R1275Q 7.22 6.66 
F1174L 7.50 6.65 
 
Note: All binding affinities listed above and in Figures 1 – 5 are given in terms of the energy released as binding occurs. 
